Introduction
============

Lung cancer is considered the second most frequent cancer for men after prostate cancer and breast cancer for women. [@B1] Non-specific cytotoxic agents are currently used for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).[@B2]-[@B4] However; side effects are the reason for some patients to postpone their treatment and in some cases to be hospitalized increasing the cost of treatment.[@B5] In the recent years targeted therapies have emerged and based on the genome of cancer specific oral agents are being administered. [@B2] Epidermal growth factor receptor status and anaplastic lymphoma kinase status are the two most investigated pathways regarding adenocarcinoma. [@B6]-[@B8] Erlotinib, gefinitib, afatinib and crizotinib are the most frequently used targeted agents.[@B7], [@B9] Erlotinib, gefinitib and afatinib have presented superiority in terms of overall survival and disease control when compared to doublet chemotherapy agents in a specific group of patients.[@B10] However; resistance to tyrosine kinase inhibitors has been observed and therefore new or alternative treatment approaches are being investigated.[@B11] These agents are considered safer in the sense that the patients have less side effects, however; they still have side effects which in some cases are dose dependent and directly compared with the positive disease control.[@B12] Regarding SCLC chemotherapy is still the considered the best first line treatment, however; several novel therapies are being investigated.[@B13]-[@B16] The role of tyrosine kinase inhibitors as neo-adjuvant or adjuvant treatment is still under investigation. One observation has to be taken into serious consideration that if chemotherapy is administered in EGFR positive patients as neo-adjuvant treatment then the mutation status will change along with the gene status of several other involved pathways with an unknown treatment effect in the future if treatment will become necessary (disease relapse). [@B17] In the study by Spaans JN et al. [@B18] it is suggested that there are no clear evidence that a patient should receive neo-adjuvant tyrosine kinase inhibitors for early stage NSCLC, however; there are evidence that patients will benefit from this oral drug administration. In the case presented by Funakoshi Y et al. [@B19] a patient received gefinitib as neo-adjuvant treatment, downstaging of the disease was observed and the patient underwent pneumonectomy. In the study by Li N et al. [@B20] it is suggested that as adjuvant treatment gefinitib can be administered with or without other chemotherapy agents. In the editorial by Martinez P et al. [@B21] it is suggested that tyrosine kinase inhibitors could be used as adjuvant treatment, however; because of the few trials which have small patient samples and with unselected patients more studies are still needed. Regarding afatinib a meta-analysis presented data where this drug could be considered as more toxic than erlotinib and gefitinib.[@B7] There are no data regarding afatinib as neo-adjuvant treatment, however; regarding adjuvant treatment there is one study by Burtness B et al. [@B22], which has not investigated lung cancer, but head and neck cancer. Maybe this study could be used for further investigation of afatinib as adjuvant treatment for NSCLC. There is one group of patients that tyrosine kinase inhibitors are still under investigation whether they would benefit or not. The "elderly" if one could set the age for this group of patients it would probably be \>75 years of age which is more or less recognized by the international medical community the cut off age that a patient should receive chemotherapy. Although in several patient cases an individualized approach is necessary if the patient has could performance status. The elderly are not considered could candidates for trials since they tend not to complete them due to side effects.[@B23]

In the current mini review we will focus on the group of patients \>70 years of age. We will present up to date studies and comment on the targeted treatment for this group of patients. (Figure [1](#F1){ref-type="fig"})

Search methods
==============

We performed an electronic article search through PubMed, Google Scholar, Medscape and Scopus databases, using combinations of the following keywords: tyrosine kinase inhobitors, erlotinib, gefitinib, afatinib, and combination of these words with the word elderly. All types of articles (randomised controlled trials, clinical observational cohort studies, review articles, case reports) were included. Selected references from identified articles were searched for further consideration indifferent of the language.

Tyrosine Kinase in the elderly (TKIs)
-------------------------------------

### Erlotinib

In the study by Yoshioka H. et al. [@B24] a very well designed study the patients and adverse effects of the TKIs were stratified according to age in three different groups as follows: a) \<75, b) 75 -84 and c) 85≥. The incidence of interstitial lung disease (ILD) (all grades) was 4.2% (\<75 years), 5.1% (75-84 years), and 3.4% (≥85 years). The mortality rate due to ILD was ≤1.7% in all age groups. Other toxicities (including rash) were similar between age groups. Therefore it was concluded that erlotinib is safe and efficient for patients \>75 years of age. In the study by Kurishima K et al. [@B25] patients receiving erlotinib were divided into two groups: a) ≤75 and b) \>75. It was observed that adverse effects were the same in both groups and the overall survival did not differ between the elderly and younger groups (median, 170 days; 95% CI: 142‑239 days vs. median, 146 days; 95% CI: 114‑185 days, respectively) (P=0.7642). Therefore it was concluded that targeted treatment is safe and efficient for this group of patients. In the study by Jackman DM. et al. [@B26] patients of \>70 years of age were included and erlotinib was administered. The most common toxicities were acneiform rash (79%) and diarrhea (69%). Four patients developed interstitial lung disease of grade 3 or higher, with one treatment-related death. It was concluded that Erlotinib merits consideration for further investigation as a first-line therapeutic option in elderly patients. In the study by Chen YM. Et al. [@B27] patients of ≥ 70 years of age were included and received either erlotinib or vinorelbine. Toxicities were generally mild in both groups. Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p \< 0.0001). It was concluded that erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC. EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received. In the study by Wheatley-Price P. et al. [@B28] two groups were formed: a) \<70 years of age and b) \>70 years of age (elderly). Response rates were similar between age groups. Elderly patients, compared with young patients, had significantly more overall and severe (grade 3 and 4) toxicity (35% *v*18%; *P*\_ .001), were more likely to discontinue treatment as a result of treatment-related toxicity (12% *v*3%; *P*\_ .0001), and had lower relative dose-intensity (64% *v*82% received \_ 90% planned dose; *P*\_ .001). It was concluded that Elderly patients treated with erlotinib gain similar survival and QOL benefits as younger patients but experience greater toxicity. In the study by Platania M. et al. [@B29] patients of ≥70 years of age were included and erlotinib was administered. Skin rash was the most common side effect (67%). Grade 3-4 adverse events were observed in 16 cases (37%). It was concluded that the use of erlotinib after chemotherapy failure in an unselected elderly population affected by NSCLC showed moderate efficacy and a moderate safety profile and therefore erlotinib represents a valid option in this setting. (Table [1](#T1){ref-type="table"})

### Gefitinib

In the study by Morikawa N. et al. [@B30] patients of \>70 years of age were included. It was observed that elevation of aspartate transaminase and/or alanine transaminase (18.3%) was the most common adverse event, and one treatment-related death (pneumonitis) occurred. It was concluded that first-line gefitinib is efficacious with acceptable toxicity in relatively fit elderly patients with advanced NSCLC harboring an EGFR mutation. In the study by Des Guetz G. et al. [@B31] patients were divided in two major groups: a) \<70 years of age and b) \>70 years of age. Patients were subdivided into three groups receiving three different drugs (gefitinib; gemcitabine; and docetaxel). It was observed that older patients had a decreased risk of progression/death compared to younger patients. Single-agent chemotherapy can be considered for patients aged ≥70years with a PS of 2. In the study by Takahashi K. et al. [@B32] patients between 72-90 years of age were included specifically to access the safety and effectiveness of gefitinib in the elderly (median age was 79.5 years). The Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS) scores improved significantly 4 weeks after the initiation of gefitinib (P = 0.037) and maintained favorably over a 12-week assessment period. The most common adverse events were rash and liver dysfunction. Although Grade 1 pneumonitis developed in one patient, no treatment-related death was observed. It was observed that first-line gefitinib therapy is effective and feasible for elderly patients harboring EGFR mutation, and improves disease-related symptoms, especially pulmonary symptoms like shortness of breath and cough. In the study by Inoue A. et al. [@B33] patients \>74 years of age were included with poor performance status and with the administration of gefitinib no treatment-related deaths were observed. Gefitinib was safe and efficient. In the study by Maemondo M. et al. [@B34] patients of \>75 years of age were included and gefitinib was administered. The common adverse events were rash, diarrhea, and liver dysfunction. One treatment-related death because of interstitial lung disease occurred. This was the first study that verified safety and efficacy of first-line treatment with gefitinib in elderly patients having advanced NSCLC with EGFR mutation. It was concluded that due to its strong antitumor activity and mild toxicity, first-line gefitinib may be preferable to standard chemotherapy for this population. (Table [2](#T2){ref-type="table"})

### Erlotinb/Gefitinb

In the study by Nakao M. et al. [@B35] patients of ≥80 years of age were included and the TKIs gefitinib and erlotinib were administered. It was observed that the administration of these agents to this group of age was acceptable, however; the authors suggest that a careful dose selection according to the overall medical condition should be made. (Table [3](#T3){ref-type="table"})

Discussion
==========

Possibly a new group of patients including \>75 years of age could be considered in the treatment of lung cancer since targeted treatment with TKIs surpass the major obstacle of chemotherapy side effects. In the study by Costa GJ et al. [@B36] patients were divided in two groups: a) \<70 years of age and b) \> 70 years of age. Platinum based chemotherapy was administered and the results indicated that "elderly patients" \>70 years of age for the first two years of drug administration had the same side effects when compared to patients of \<70 and treatment was well tolerated. Therefore it was proposed that "elderly patients" \> 70 years of age could choose non-specific cytotoxic agents for treatment of NSCLC. In the study by Yellen SB. Et al. [@B37] patients were divided into two groups: a) \<65 years of age and b) \> 65. It was observed that most patients in group b were willing to have chemotherapy treatment, however; when they were asked to choose between survival and quality of life, most of them chose quality of life. In all the studies included patients were harboring epidermal growth factor receptor (EGFR) mutations. In the study by Wheatley-Price P. et al. [@B28] severe toxicity was observed in a number of patients and therefore dose modification was required. In the study by Bai H. et al. [@B38] gastric bleeding was observed by the administration of both erlotinib and gefitinib. Erlotinib is known to cause gastric bleeding and it is dose dependent. A major issue that we identified during our search firstly is that there is no clear definition which patient is considered "elder". In the U.S.A elderly were considered mostly patients \>70, while in Europe \>75 years of age. Secondly very few studies were designed especially with the purpose to identify whether TKIs should be definitely administered to the elderly. One of the reasons is that in general studies conducted with patients more than 70 years of age are difficult to recruit and maintain the follow up of the patients.[@B23] Thirdly in a number of studies the first line treatment of choice was chemotherapy and the second line was a TKI. However; as previously presented the status of the EGFR changes after chemotherapy, therefore we need more studies without previously treated elderly.[@B17] Moreover; there are no data concerning afatinib and the elderly patients. Afatinib is a very new drug in the market and current data indicate that is slightly more toxic than erlotinib and gefitinib.[@B39] Based on the current information we suggest that TKIs should administered in the elderly, and with the word elderly we propose the age of 75. The treating medical doctor has to evaluate the performance status of a patient and decide the best treatment in several cases indifferent of the age. TKIs in most studies presented safety and efficiency and of course dose modification should be made when necessary. Comorbidities should be considered in any case especially in this group of patients and the treating physician should act accordingly.

![**EGFR;** Epidermal Growth Factor, **AKT;** kinase-interacting protein1, **PTEN;** Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, **PI3K;** Phosphatidylinositol-3-kinases, PI 3-kinases, PI(3)Ks, **RAS;** Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours, **RAF;** Raf kinases (more avidly C-Raf than B-Raf), **MAPK/ERK;** extracellular signal-regulated kinases , **TKI;** Tyrosi**ne kinase inhibitor, STAT;**Signal Transducers and Activators of Transcription. **MEK;** mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2.](jcav07p0687g001){#F1}

###### 

Erlotinib in the elderly

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                     Patients                                                                                      Adverse effects                                                                                                                     Efficiency                                                                                                                                                                                                   Proposal                                                                                                                                                                                               Ref
  -------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----
  Yoshioka H. et al.         (\<75 years, n = 7848; 75-84 years,n = 1911; ≥85 years, n = 148                               incidence of ILD (all grades) was4.2% (\<75 years), 5.1% (75-84 years), and 3.4% (≥85 years), rash was similar between age groups   median PFS was65 days (95% confidence interval \[CI\], 62-68) for patients aged \<75 years, 74 days (95% CI, 69-82) forpatients aged 75-84 years, and 72 days (95% CI, 56-93) for patients aged ≥85 years.   Erlotinib could be considered for elderly patients with recurrent/advancedNSCLC                                                                                                                        24

  KURISHIMA K. et al.        (≥75 years, n=74) and a younger group of patients (\<75 years, n=233)                         adverse events did not differ in incidence between the groups and were manageable, regardless of age                                The overall survival did not differ between the elderly and younger groups (median, 170 days; 95% CI: 142‑239 days vs. median, 146 days; 95% CI: 114‑185 days, respectively) (P=0.7642)                      Among the NSCLC patients receiving erlotinib treatment, the outcomes of the elderly (≥75 years) and younger (\<75 years) groups of patients were similar in our population‑based observational study   25

  Jackman DM. et al.         phase II, multicenter, open-label study of chemotherapy-naı¨ve patients with non-smallcell\   The most common toxicities were acneiform rash (79%) and diarrhea (69%).\                                                           eight partial responses (10%), and an additional 33 patients (41%) had stable disease for 2 months\                                                                                                          Erlotinib merits consideration for further investigation as a first-line\                                                                                                                              26
                             lung cancer (NSCLC) and age \_ 70 years who were treated with erlotinib and evaluated to\     Four patients developed interstitial lung disease of grade 3 or higher, with one treatment-related\                                 or longer. The median TTP was 3.5 months (95% CI, 2.0 to 5.5 months). The median survival time\                                                                                                              therapeutic option in elderly patients                                                                                                                                                                 
                             determine the median, 1-year, and 2-year survival                                             death                                                                                                                               was 10.9 months (95% CI, 7.8 to 14.6 months). The 1- and 2- year survival rates were 46% and\                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                               19%, respectively                                                                                                                                                                                                                                                                                                                                                                                                   

  Wheatley-Price P. et al.   two age groups: \_ 70 years (elderly) or less than 70 years (young)                           Elderly patients, compared with young patients, had significantly\                                                                  no significant difference between age groups randomly assigned\                                                                                                                                              Elderly patients treated with erlotinib gain similar survival and QOL benefits as younger patients\                                                                                                    28
                                                                                                                           more overall and severe (grade 3 and 4) toxicity (35% *v*18%; *P*\_ .001), were more likely to\                                     to erlotinib or placebo in progression-free survival (elderly: 3.0 *v*2.1 months; hazard ratio \[HR\] \_ 0.63;\                                                                                              but experience greater toxicity                                                                                                                                                                        
                                                                                                                           discontinue treatment as a result of treatment-related toxicity (12% *v*3%; *P*\_ .0001), and had lower\                            95% CI, 0.44 to 0.90; *P*\_ .009; young: 2.1 *v*1.8 months; HR \_ 0.64; 95% CI, 0.53 to 0.76; *P*\_ .0001;\                                                                                                                                                                                                                                                                                                         
                                                                                                                           relative dose-intensity (64% *v*82% received \_ 90% planned dose; *P*\_ .001                                                        interaction, *P*\_.77) or OS (elderly: 7.6 *v*5.0 months; HR_0.92; 95% CI, 0.64 to 1.34; *P*\_.67; young:\                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                               6.4 *v*4.7 months; HR \_ 0.73; 95% CI, 0.61 to 0.89; *P*\_ .0014; interaction, *P*\_ .31).                                                                                                                                                                                                                                                                                                                          

  Platania M. et al.         group of\                                                                                     Skin rash was the most common side effect\                                                                                          The median overall survival and the median\                                                                                                                                                                  factors such as\                                                                                                                                                                                       29
                             pretreated elderly metastatic non-small cell lung cancer\                                     (67%). Grade 3-4 adverse events were observed in 16 cases\                                                                          progression-free survival were 8.4 months (CI 95%: 0.7-\                                                                                                                                                     biological information, comorbidities and concomitant\                                                                                                                                                 
                             (NSCLC) patients admitted to our institution and treated\                                     (37%).                                                                                                                              43.6) and 3 months (CI 95%: 0.4-28.4), respectively.\                                                                                                                                                        medications need to be carefully take into consideration in\                                                                                                                                           
                             with erlotinib at standard daily/dose (≥70 years of age)                                                                                                                                                                          Patients with adenocarcinoma achieved the best disease\                                                                                                                                                      this particular subset of cancer patients                                                                                                                                                              
                                                                                                                                                                                                                                                               control rate (p=0.027), while not/former smokers showed a\                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                               better response (p=0.069)                                                                                                                                                                                                                                                                                                                                                                                           

  Chen YM. et al.            Chemonaive Taiwanese patients aged 70 years or older\                                         Toxicities were generally mild in both groups                                                                                       Objective\                                                                                                                                                                                                   Erlotinib is highly effective compared with oral vinorelbine\                                                                                                                                          27
                             who had advanced NSCLC were randomized to receive either oral\                                                                                                                                                                    response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V\                                                                                                                                           in elderly, chemonaive, Taiwanese patients with NSCLC.\                                                                                                                                                
                             erlotinib 150 mg (E) daily or oral vinorelbine 60 mg/m2 (V) on days\                                                                                                                                                              (*p*\_ 0.0388). Median progression-free survival (PFS) was 4.57\                                                                                                                                             *EGFR*-mutated patients had better survival than those with *EGFR*\                                                                                                                                    
                             1 and 8 every 3 weeks                                                                                                                                                                                                             months in E and 2.53 months in V (*p*\_ 0.0287), with an 80.6%\                                                                                                                                              wild-type disease, regardless of the treatment received                                                                                                                                                
                                                                                                                                                                                                                                                               increase in median PFS for E compared with V. Median survival\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                               time was 11.67 months in E and 9.3 months in V (*p*\_ 0.6975)                                                                                                                                                                                                                                                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Gefinitib in the elderly

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                Patients                                                                                                                                                                                                                                                                                                            Adverse effects                                                                                                                                                                                                                                                                                               Efficiency                                                                                                                                                                                                                                                   Proposal                                                                                                                                                                                                                        Ref
  --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----
  Morikawa M. et al.    pooled data from one Phase III and two Phase II studies of 71 patients aged ≥ 70 years with a performance status of 0 - 2                                                                                                                                                                                           Elevation of aspartate transaminase and/or alanine transaminase (18.3%) was the most common adverse event, and one treatment-related death (pneumonitis) occurred. Time to 9.1% deterioration in the QoL domains of pain and dyspnea, anxiety, and daily functioning was similar between the two age groups   Median PFS (14.3 vs 5.7 months, p \< 0.001) and overall RR (73.2 vs 26.5%, p \< 0.001) in the gefitinib group were superior to those in the standard chemotherapy group, whereas median OS was not significantly different (30.8 vs 26.4 months, p = 0.42)   First-line gefitinib is efficacious with acceptable toxicity in relatively fit elderly patients with advanced NSCLC harboring an EGFR mutation                                                                                  30

  Des Guetz G. et al.   two subgroups aged \<70 years (younger, n = 56) and ≥70 years\                                                                                                                                                                                                                                                      Toxicity did not differ between\                                                                                                                                                                                                                                                                              Progression-free survival (PFS) was 1.4 months (95% CI: 1.1-1.9) for younger compared to\                                                                                                                                                                    Older patients had a decreased risk of progression/death compared to younger\                                                                                                                                                   31
                        (older, n = 71)                                                                                                                                                                                                                                                                                                     younger and older patients                                                                                                                                                                                                                                                                                    2.3 months (95% CI: 2.1-2.9) for elderly patients. Overall survival (OS) was 2.0 months (95%\                                                                                                                                                                patients. Single-agent chemotherapy can be considered for patients aged ≥70 years with a\                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          CI: 1.5-2.4) and 3.7 months (95% CI: 2.4-4.8), respectively                                                                                                                                                                                                  PS of 2                                                                                                                                                                                                                         

  Takahashi K. et al.   Chemotherapy-naοve patients aged\                                                                                                                                                                                                                                                                                   The most common adverse events\                                                                                                                                                                                                                                                                               Overall response rate\                                                                                                                                                                                                                                       First-line gefitinib therapy is effective and\                                                                                                                                                                                  32
                        70 years or older with stage IIIB or IV NSCLC harboring\                                                                                                                                                                                                                                                            were rash and liver dysfunction. Although Grade 1 pneumonitis\                                                                                                                                                                                                                                                was 70 % (95 % CI 45.7-88.1 %), and the disease control\                                                                                                                                                                                                     feasible for elderly patients harboring EGFR mutation, and\                                                                                                                                                                     
                        EGFR-activating mutation were enrolled and treated with\                                                                                                                                                                                                                                                            developed in one patient, no treatment-related\                                                                                                                                                                                                                                                               rate was 90 % (95 % CI 68.3-98.7 %). The median progression-\                                                                                                                                                                                                improves disease-related symptoms, especially pulmonary\                                                                                                                                                                        
                        250 mg of gefitinib daily until disease progression                                                                                                                                                                                                                                                                 death was observed                                                                                                                                                                                                                                                                                            free survival and overall survival time were 10.0\                                                                                                                                                                                                           symptoms like shortness of breath and cough                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          and 26.4 months, respectively                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Maemondo M et al.     Chemotherapy-naive patients aged 75 years or older with performance status 0 to 1 and advanced NSCLC harboring EGFR mutations, as determined by the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method, were enrolled. The enrolled patients received 250 mg/day of gefitinib orally   The common adverse events were rash, diarrhea, and liver dysfunction. One treatment-related death because of interstitial lung disease occurred                                                                                                                                                               The overall response rate was 74% (95% confidence interval, 58%-91%), and the disease control rate was 90%. The median progression-free survival was 12.3 months                                                                                             Considering its strong antitumor activity and mild toxicity, first-line gefitinib may be preferable to standard chemotherapy for this population                                                                                34

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Because there previously has been no standard treatment for these patients with short life expectancy other than best supportive care, examination of EGFR mutations as a biomarker is recommended in this patient population   

  Inoue A. et al.       Oncology Group PS 3 to 4, 75 to 79 years of age with PS 2 to 4, and \_ 80 years of age with PS 1 to\                                                                                                                                                                                                                No treatment-related deaths were observed                                                                                                                                                                                                                                                                     The overall response rate was 66% (90% CI, 51% to 80%), and the\                                                                                                                                                                                             Because there previously has been no standard treatment for these\                                                                                                                                                              33
                        4) who had *EGFR*mutations were enrolled and received gefitinib (250 mg/d) alone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  disease control rate was 90%. PS improvement rate was 79% (*P*\_ .00005); in particular, 68% of\                                                                                                                                                             patients with short life expectancy other than best supportive care, examination of *EGFR*\                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          the 22 patients improved from \_ PS 3 at baseline to \_ PS 1. The median progression-free survival,\                                                                                                                                                         mutations as a biomarker is recommended in this patient population                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          median survival time, and 1-year survival rate were 6.5 months, 17.8 months, and 63%,\                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          respectively                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Erlotinib/Gefitinib in the elderly

  Author            Patients                                                                                                                  Adverse effects                                                                                                                                                                                                                                               Efficiency                                                                                                                                                                                                                                    Proposal                                                                                                                                                                                            Ref
  ----------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----
  Nakao M. et al.   This retrospective study aimed to evaluate the efficacy and feasibility of EGFR‑TKIs for NSCLC patients aged ≥80 years.   Adverse events ≥grade 2 were as follows: skin toxicities, 12 patients; liver function test abnormalities, 7 patients; anorexia, 3 patients; and diarrhea, 2 patients. Dose reduction of EGFR‑TKIs due to adverse events was required in 15 patients (71.4%)   In total, 14 (66.7%), 5 (23.8%) and 2 patients (9.5%) displayed partial response, stable disease and progressive disease, respectively. The median progression‑free survival was 182 days, whereas the median overall survival was 371 days   Although gefitinib and erlotinib therapy may be beneficial in patients aged ≥80 years, EGFR‑TKI dose modification may be necessary according to the overall medical condition of elderly patients   35
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